01 (Image 01)
Nifedipine Tablet, Extended Release
Product Images NDC 50090-6201
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 50090-6201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
02 (Image 02)
This text shows the adverse effects reported by patients who took nifedipine extended-release tablets compared to those who took placebo. The most common adverse effects reported by patients who took nifedipine were constipation, headache, and nausea. However, fatigue, dizziness, and headache were also reported. Patients taking placebo reported similar adverse effects but with a slightly lower incidence.*
03 (Image 03)
This appears to be a table showing the percentage of patients experiencing various adverse effects while taking nifedipine capsules versus a placebo. Adverse effects include dizziness, flushing, headache, weakness, nausea, muscle cramps, and more. The number of patients used in the study (N) is also given for both groups.*
Label Image (Lbl500906201)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
